Literature DB >> 21895016

Structure-based design of pseudopeptidic inhibitors for SIRT1 and SIRT2.

Tero Huhtiniemi1, Heikki S Salo, Tiina Suuronen, Antti Poso, Antero Salminen, Jukka Leppänen, Elina Jarho, Maija Lahtela-Kakkonen.   

Abstract

The lack of substrate-bound crystal structures of SIRT1 and SIRT2 complicates the drug design for these targets. In this work, we aim to study whether SIRT3 could serve as a target structure in the design of substrate based pseudopeptidic inhibitors of SIRT1 and SIRT2. We created a binding hypothesis for pseudopeptidic inhibitors, synthesized a series of inhibitors, and studied how well the fulfillment of the binding criteria proposed by the hypothesis correlated with the in vitro inhibitory activities. The chosen approach was further validated by studying docking results between 12 different SIRT3, Sir2Tm, SIRT1 and SIRT2 X-ray structures and homology models in different conformational forms. It was concluded that the created binding hypothesis can be used in the design of the substrate based inhibitors of SIRT1 and SIRT2 although there are some reservations, and it is better to use the substrate-bound structure of SIRT3 instead of the available apo-SIRT2 as the target structure.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21895016     DOI: 10.1021/jm200590k

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  16 in total

1.  3-(N-arylsulfamoyl)benzamides, inhibitors of human sirtuin type 2 (SIRT2).

Authors:  Soo Hyuk Choi; Luisa Quinti; Aleksey G Kazantsev; Richard B Silverman
Journal:  Bioorg Med Chem Lett       Date:  2012-03-03       Impact factor: 2.823

Review 2.  Sirtuin catalysis and regulation.

Authors:  Jessica L Feldman; Kristin E Dittenhafer-Reed; John M Denu
Journal:  J Biol Chem       Date:  2012-10-18       Impact factor: 5.157

3.  Peptides and Pseudopeptides as SIRT6 Deacetylation Inhibitors.

Authors:  Piia Kokkonen; Minna Rahnasto-Rilla; Päivi H Kiviranta; Tero Huhtiniemi; Tuomo Laitinen; Antti Poso; Elina Jarho; Maija Lahtela-Kakkonen
Journal:  ACS Med Chem Lett       Date:  2012-10-23       Impact factor: 4.345

4.  In silico design and in vitro assessment of anti-Helicobacter pylori compounds as potential small-molecule arginase inhibitors.

Authors:  Ana Thereza Fiori-Duarte; João Paulo de Oliveira Guarnieri; Jessica Rodrigues Pereira de Oliveira Borlot; Marcelo Lancellotti; Ricardo Pereira Rodrigues; Rodrigo Rezende Kitagawa; Daniel Fábio Kawano
Journal:  Mol Divers       Date:  2022-01-08       Impact factor: 2.943

Review 5.  Sirtuin inhibitors as anticancer agents.

Authors:  Jing Hu; Hui Jing; Hening Lin
Journal:  Future Med Chem       Date:  2014-05       Impact factor: 3.808

6.  [Dexmedetomidine alleviates postoperative cognitive dysfunction in aged rats probably via silent information regulator 1 pathway].

Authors:  Sitong Fang; Yong Chen; Peng Yao; Yiling Li; Yujun Yang; Guohai Xu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-08-30

7.  Discovery of 5-Benzylidene-2-phenyl-1,3-dioxane-4,6-diones as Highly Potent and Selective SIRT1 Inhibitors.

Authors:  Chunpu Li; Sha-Sha Hu; Lisheng Yang; Min Wang; Jian-Dong Long; Bing Wang; Haozhen Han; Haoran Zhu; Sen Zhao; Jing-Gen Liu; Dongxiang Liu; Hong Liu
Journal:  ACS Med Chem Lett       Date:  2021-03-01       Impact factor: 4.345

Review 8.  Emerging roles of SIRT6 in human diseases and its modulators.

Authors:  Gang Liu; Haiying Chen; Hua Liu; Wenbo Zhang; Jia Zhou
Journal:  Med Res Rev       Date:  2020-12-16       Impact factor: 12.944

Review 9.  Rejuvenating sirtuins: the rise of a new family of cancer drug targets.

Authors:  Santina Bruzzone; Marco Daniele Parenti; Alessia Grozio; Alberto Ballestrero; Inga Bauer; Alberto Del Rio; Alessio Nencioni
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

10.  Structures, substrates, and regulators of Mammalian sirtuins - opportunities and challenges for drug development.

Authors:  Sébastien Moniot; Michael Weyand; Clemens Steegborn
Journal:  Front Pharmacol       Date:  2012-02-09       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.